Weill Cornell Medicine/NewYork-Presbyterian; Englander Institute of Precision Medicine
Dr. Pashtoon Kasi, MD, MS is an oncologist and researcher at Weill Cornell Medicine and NewYork-Presbyterian Hospital. He focuses on treating patients with gastrointestinal (GI) cancers and the treatment of patients with novel drugs/early-phase clinical trials. At Weill Cornell Medicine, Dr. Kasi additionally serves as the Director for Colorectal Cancer Research, as well as Precision Medicine Director for Liquid Biopsy Research at the Englander Institute of Precision Medicine.
Dr. Kasi received his medical degree from Aga Khan University (AKU) in Pakistan in 2006. Following this he completed his residency at the the University of Pittsburgh Medical Center (UPMC). In 2016 he completed a fellowship in oncology and hematology at the Mayo Clinic. At the Mayo Clinic, he also completed a post-doctoral master’s program at the Mayo School of Graduate Medical Education (MSGME) in clinical and translational sciences (Masters in Basic Sciences).
Prior to joining Weill Cornell Medicine, Dr. Kasi served as an Associate Professor at the University of Iowa, and Assistant Professor of Medicine and Oncology at both University of Iowa and Mayo Clinic. He was ofelect few who were appointed to the Assistant Professor of Oncology and Assistant Professor of Medicine at the Mayo Clinic during his fellowship due to his research/academic achievements.
Dr. Kasi’s research focus has been on “liquid biopsies” [(circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs)], alongside developing and conducting clinical trials focused on precision oncology. Dr. Kasi is an author/editor of several books, and has over 110 publications in leading peer-reviewed journals.
Session 5: Clinical Trial Landscape Incorporating ctDNA
Wednesday, August 2, 2023
2:45 PM – 3:30 PM ET